||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about Synergy Hlth. (London Stock Exchange): 0 recent articles
|analyst: Investors Chronicle says Sell
Shares in cleaning and sterilisation specialist Synergy Health (SYR) have been notably strong performers lately, outpacing shares in similar companies by 20 per cent over the past quarter on the back of some promising deals in new markets. True, Synergy almost certainly has a solid future in its key markets, but, in the medium-term, the share rating has moved too far ahead of the group's growth prospects. Really brave punters might try 'short selling' the stock; meanwhile, shareholders might simply opt to sell.
The trigger for the big share-price move was Synergy's decisive entry into the US hospitals market. The acquisition of SRI/Surgical Express, in particular, for $25m (£17m) got the City's admiration, especially because the price paid looked good for a business generating sales of more than $100m.
However, it is not clear what effect the expansion will have on Synergy's underlying profit margins. These were more than 15 per cent in the first half of 2012-13, but there is a risk that the peculiarities of the US business could eat into them. This is because most US hospitals, unlike those in Synergy's core business with the NHS, have their own sterilising and cleansing facilities on-site. That means Synergy would be paid a fee as a service provider, rather than as a more lucrative full-facility operator.
There is no doubt that the US market is far larger than anything Synergy has entered so far and the opportunities are there. However, the question hanging over the States-side project is whether investors have taken into account the amount of investment needed over the next few years to bring the service up to Synergy's standards. That could generate big one-off costs that may not be adequately priced in.
As support services businesses go, Synergy is unusual because a lot of its capital is tied up in tangible assets. That's because often it has to fund and build hospital cleaning facilities itself for the contracts it wins. That means lots of upfront spending in order to grow sales, as each new contract can mean another round of construction.
Analysts at broker CanaccordGenuity estimate that to achieve an adequate cashflow return on its capital of around 8 per cent, the company must invest between £15m and £30m annually to generate the required income. This inhibits shareholders' returns as the lead time between winning a contract and starting operations is between 18 months to two years. CanaccordGenuity estimates that the company will clock up capital spending of £75m over the next three years. Given the lag between spending and revenue-generation, sales growth will be deferred, making Synergy much more cyclical than is generally perceived.
Synergy also has its share of immediate problems resulting from austerity in the European Union. This affects its Dutch business supplying hospital linen, in particular. Meanwhile, a spending squeeze in the NHS, while not affecting existing contracts due to the importance for patient care, could slow the pipeline of new work that Synergy could bid for.
Share tip summary
Trading on almost 17 times forecast underlying earnings, Synergy's shares are rated just above the UK average for the healthcare services sector at a time when significant parts of its operations face slowing growth in its established markets. Granted, expansion into the US seems like a good move given the size of the market, and European austerity will not last for ever. Yet the rating has moved to a level that is vulnerable to correction if the company fails to outperform the market's expectations. Given the consistently high capital spending Synergy must undertake, the possibility of disappointment is higher than average. Sell.|
|milacs: Good looking chart and no followers.
Will the share price push through the 800p barrier this time.
|assegai: Interims out to day are very positive.
Key points are:
Revenue up 52% to £102 million.
Operating profit up 115% to £15.3 million.
Profit after taxation up 93% to £8.5 million.
Strong statement expecting good year end results.
The share price now is relatively low so well worth taking a detailed look at.|
|6million dollarman: THE WEEKLY BB REVIEW - GREYSTONE
As Synergy Healthcare - Keep Yer eye's on this one Trading Starts August 20th (SYR) shows, it was an inauspicious start for the newcomer. 6million dollarman was fan numero uno and looking at a long-term investment rather than a quick shot in the bionic arm. Dil was persudaded by the silver tongue of stustu that it was an interesting sector and northwards showed some interest too, but otherwise this one seemed to pass by the PBB without much comment. A good end to the week pushed the share price back to the issue price. It will be interesting to see how it fares in the lead up to the interim results which are due soon. Certainly worth adding to my Monitor in the short-term.
Should have kept mi mouth shut $%-)) Thanks Greystone
Synergy Health share price data is direct from the London Stock Exchange